Related Experiment Videos

Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase

S Sadoni1, I Kaczmarek, O Delgado

  • 1Department of Cardiac Surgery, Grosshadern University Hospital, Ludwig-Maximilians-University, Munich, Germany. Sebastian.Sadoni@med.uni-muenchen.de

Transplantation Proceedings
|March 17, 2007
PubMed

Insights

Switching heart transplant patients to fluvastatin safely reduced elevated creatine-kinase levels. This statin conversion may help patients continue lipid-lowering therapy despite side effects from other statins.

Area of Science:

  • Cardiology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Statins are crucial for reducing mortality and transplant vasculopathy in heart transplant recipients.
  • Common statins (simvastatin, atorvastatin) interact with immunosuppressants, causing side effects and therapy withdrawal.
  • Fluvastatin offers a safer alternative due to minimal cytochrome P-450 3A4 pathway interaction.

Purpose of the Study:

  • To evaluate the impact of switching heart transplant patients with elevated creatine-kinase (CK) to fluvastatin.
  • To assess the safety and efficacy of fluvastatin in managing statin-related side effects in this population.

Main Methods:

  • 23 heart transplant patients with elevated CK levels were switched to an equivalent dose of fluvastatin.
  • Creatine-kinase, lipid profiles (HDL, LDL, triglycerides), ALT, AST, and creatinine were monitored at baseline and at 3, 6, 9, and 12 months.

Main Results:

  • Creatine-kinase levels significantly decreased by 25% at 6 months and 38% at 9 months (P < .05).
  • HDL-cholesterol significantly decreased (8% at 6 months, 23% at 9 months; P < .05).
  • Triglycerides showed a significant increase at 3 months (18%; P < .05), with no significant changes in other lipid parameters or liver/kidney function markers.

Conclusions:

  • Conversion to fluvastatin is safe and effectively reduces elevated creatine-kinase in heart transplant recipients.
  • Fluvastatin may help maintain lipid-lowering therapy in patients experiencing side effects from conventional statins.
  • Potential initial impacts on HDL-cholesterol and triglycerides should be considered during fluvastatin therapy.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance (Clcr), a...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...